A Phase 3, Double-Blind 2 Arm Study in the Treatment of Acne Vulgaris

This is a multi-center, randomized, double-blind, vehicle-controlled, 12-week study designed
to assess the safety, efficacy, and tolerability of IDP-123 Lotion and IDP-123Vehicle Lotion.
To be eligible for the study subjects must be at least 9 years of age and have a clinical
diagnosis of moderate to severe acne.

Inclusion Criteria:

1. Male or female at least 9 years of age and older;

2. Written and verbal informed consent must be obtained. Subjects less than age of
consent must sign an assent for the study and a parent or a legal guardian must sign
the informed consent (if subject reaches age of consent during the study they should
be re-consented at the next study visit);

3. Subject must have a score of 3 (moderate) or 4 (severe) on the Evaluator's Global
Severity assessment at the baseline visit;

4. Subjects with facial acne inflammatory lesion (papules, pustules, and nodules) count
no less than 20 but no more than 50;

5. Subjects with facial acne non-inflammatory lesion (open and closed comedones) count no
less than 25 but no more than 100;

Exclusion Criteria:

1. Use of an investigational drug or device within 30 days of enrollment or participation
in a research study concurrent with this study;

2. Any dermatological conditions on the face that could interfere with clinical
evaluations such as acne conglobata, acne fulminans, secondary acne, perioral
dermatitis, clinically significant rosacea, gram-negative folliculitis, dermatitis,
eczema;

3. Any underlying disease(s) or some other dermatological condition of the face that
requires the use of interfering topical or systemic therapy or makes evaluations and
lesion count inconclusive;

4. Subjects with a facial beard or mustache that could interfere with the study
assessments;

5. Subjects with more than two (2) facial nodules;

6. Evidence or history of cosmetic-related acne;